The IMPACT Study
A proven early treatment alternative to BPH medications2
The only leading BPH minimally invasive surgical therapy (MIST) with consistent durability in the real-world and clinical trials2,3
A safe, effective treatment,2 providing a superior patient experience* among leading BPH procedures3-5
One of the most studied BPH MIST procedures with 145+ peer reviewed and clinical publications
A Proven Early Treatment Alternative to Medications2
98%
of men seeing a doctor for BPH are treated with medications or watchful waiting1
Medications like alpha blockers, 5-ARIs or combination therapy are first-line treatment for patients with BPH symptoms, but they can come with some significant tradeoffs.
|
|
|
|
The IMPACT Study
This study represents the largest head-to-head RCT comparing efficacy, safety and patient experience* after UroLift™ PUL and medical therapy (alpha blocker Tamsulosin).29 Preliminary data suggest that UroLift™ PUL yields advantages in the first three months:
- Better symptom relief and quality of life improvements29
- Higher patient satisfaction and goal attainment29
- More improvements in daily activities29
Despite technological innovation, only 2% of men seeing a doctor for BPH are treated with a surgical intervention1
UroLift™ System
Market leading minimally invasive BPH procedure1
Grade 3+ or Serious Adverse Events:
0.7%2
—
Sexual Function:
0% EjD**2
TURP
Traditional invasive surgery since 1926
Grade 3+ or Serious Adverse Events:
7.6%19-20
–
Sexual Function:
36% EjD**19-20
Aquablation
Robotic waterjet ablation comparable to traditional invasive surgeries
Grade 3+ or Serious Adverse Events:
6.9%19-20
—
Sexual Function:
10% EjD**19-20
The graphic is for educational purposes only. Direct comparisons of studies cannot be made.
**De novo ED or EjDamong sexually active men
1 in 20
Did you know? New data shows that within one year of BPH surgery, 1 in 20 patients may require retreatment regardless of the procedure type.3
The Only Leading BPH MIST With Consistent Durability in Real World and Clinical Trials2,3
Provides Superior Patient Experience* Among Leading BPH Procedures3-5
Rapid relief with a low risk profile22-23
Lowest catheter rate of the leading BPH procedures2,23-27
Preservation of sexual function***2
Patient Safety
Once procedure volume is factored in, the UroLift™ System has the lowest rates of mild, moderate, and severe complications on a per case basis from 2019-202228+
The UroLift™ System had the lowest post-procedural complication rate at one year compared to other procedures.3